Direct oral anticoagulants and venous thromboembolism

Massimo Franchini, Pier Mannuccio Mannucci

Research output: Contribution to journalReview article

Abstract

Venous thromboembolism (VTE), consisting of deep vein thrombosis and pulmonary embolism, is a major clinical concern associated with significant morbidity and mortality. The cornerstone of management of VTE is anticoagulation, and traditional anticoagulants include parenteral heparins and oral vitamin K antagonists. Recently, new oral anticoagulant drugs have been developed and licensed, including direct factor Xa inhibitors (e.g. rivaroxaban, apixaban and edoxaban) and thrombin inhibitors (e.g. dabigatran etexilate). This narrative review focusses on the characteristics of these direct anticoagulants and the main results of published clinical studies on their use in the prevention and treatment of VTE.

Original languageEnglish
Pages (from-to)295-302
Number of pages8
JournalEuropean Respiratory Review
Volume25
Issue number141
DOIs
Publication statusPublished - Sep 1 2016

ASJC Scopus subject areas

  • Medicine(all)
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Direct oral anticoagulants and venous thromboembolism'. Together they form a unique fingerprint.

  • Cite this